Kodiak Sciences completes enrollment for KSI-301 safety study in retinal disease
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability study of its innovative retinal disease drug, ... Read More
FDA approves updated label for Regeneron’s EYLEA treating wet AMD
In a significant development for ophthalmic care, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License ... Read More